CPA
WGS icon

Capital Performance Advisors’s GeneDx Holdings WGS Stock Holding History

Capital Performance Advisors’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-165
Closed -$7K – 2682
2024
Q3 		$7K Buy
+165
New +$5.57K ﹤0.01% 971

Other funds holding WGS

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Capital Performance Advisors's WGS Position: Q4 2024 in Review

Capital Performance Advisors sold out of GeneDx Holdings (WGS) in Q4 2024, closing a stake of 165 shares — an estimated $7K sold.

Capital Performance Advisors first reported a position in WGS in Q3 2024 and held it in 1 quarter. The position peaked at $7K in Q3 2024. 199 funds tracked by Wall St. Rank hold WGS as of Q4 2024.

  • Capital Performance Advisors reported no remaining GeneDx Holdings position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 165 GeneDx Holdings shares in Q4 2024, an estimated $7K.
  • Capital Performance Advisors first reported a position in GeneDx Holdings in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's GeneDx Holdings position peaked at $7K in Q3 2024.
  • 199 funds tracked by Wall St. Rank held GeneDx Holdings as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.